Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States - 12/03/25
, Karishma Desai b, Chanadda Chinthammit a, Michael Grabner b, Grace Stockbower b, Xuanyao He a, Donna Mojdami a, Cachet Wenziger b, Theresa Hunter Gibble aAbstract |
Aim |
To understand treatment patterns and effectiveness of tirzepatide among people without type 2 diabetes (T2D) in the US.
Methods |
This retrospective, observational, descriptive study used the Healthcare Integrated Research Database (index date: first-observed tirzepatide claim; index period: May 13, 2022–May 24, 2023). Key eligibility criteria were: age ≥ 18 years; ≥ 1 tirzepatide claim; no T2D diagnosis codes or glycated hemoglobin ≥ 6.5 %, no anti-diabetes medications (except metformin); and continuous medical/pharmacy enrollment for ≥ 12 months pre-index (Overall cohort). Tirzepatide persistence and utilization (6-months post-index) were assessed among obesity management medication (OMM)-eligible individuals (body mass index [BMI] ≥ 30 kg/m2, or ≥ 27 kg/m2 with ≥ 1 obesity-related complication [ORC]; OMM-eligible cohort). Tirzepatide effectiveness was assessed among individuals who were OMM-eligible, naive to glucagon-like peptide-1 receptor agonists, and persistent on tirzepatide for ≥6 months (Persistent+GLP-1 naive cohort).
Results |
The overall cohort included 4,177 individuals with mean age 46.0 years, 75.6 % female, and mean BMI 37.1 kg/m2. At baseline, 73.8 % of individuals had ≥ 1 ORC while 51.0 % had ≥ 2 ORCs. Persistence in the OMM-eligible cohort was 73.8 %; by the sixth prescription fill, 56.2 % were receiving < 10 mg tirzepatide. Individuals in the Persistent+GLP-1 naive cohort with pre- and post-index weight and BMI measurements (n = 200) achieved mean weight reduction of 12.9 % at 6-months post-index (≥ 5 %: 88.5 %; ≥ 10 %: 69.0 %).
Conclusion |
Real-world evidence suggests multimorbidity among tirzepatide initiators, slower tirzepatide dose escalation than in clinical trials, and clinically meaningful weight reduction among people persisting on tirzepatide for ≥ 6 months.
Le texte complet de cet article est disponible en PDF.Keywords : Obesity, Real-world, Tirzepatide, Weight reduction, Without type 2 diabetes
Plan
Vol 51 - N° 3
Article 101636- mai 2025 Retour au numéro
Article précédent
- Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data
- Emmanuel Disse, Judith Aron-Wisnewsky, David Jacobi, Karine Clément, Martine Laville, Cyril Gauthier, François Pattou, Julie Molleville, Melissa Akerib, Lysiane Jubin, Blandine Gatta-Cherifi, Bénédicte Gaborit, Emilie Montastier, Fabien Stenard, Claire Carette, Najate Achamrah, Antoine Avignon, Sébastien Czernichow, SEMAFEAP Study Group, Camille Sollier, Bérénice Segrestin, Anne Dutour, Jean-Baptiste Bonnet, Charles Barsamian, Pierre Belassen, Diana Shenouda, Ana Estrade, Alain Pradignac, Vanessa Folope, Najate Achamrah, Naima Oukhouyadaoud, Rudy Caillet, Mohamed Zerguine, Marie-Claude Brindisi, Séverine Ledoux, Maud Monsaingeon-Henry, Agnès Sallé, Magalie Miolanne, Mickael Som, Séverine Andrieux, Marion Bretault, Anne-Cécile Paepegaey, Yann Matussiere, Anne-Laure Sberna, Geraldine Vitellius, Syrine Jarraya, Nicolas Chevalier, Véronique Taillard, Anca Montagnier, Marie Guillouche, Géraldine Lévy, Pauline Suzeau, Alexandre Schwanke, Héléna Mosbah, Geoffroy Boulate, Said Bekka, Laurène Bosc, Ibrahim Hamadeh, Thomas Leroi, Virginie Castera, Frédérique Olivier, Vincent Appavoupoulle, Alexandre Jehl, Océane Lheveder, Marie-Laure Lalanne-Mistrih, Audrey Lamoliate, Patricia Degrelle, Jean-Sébastien Lanne, Nadia Sabbah, Elias Barrak, Lise Pagniez, Salvatore Avallone, Dominique Boute, Lyse Bordier
- Advancing type 1 diabetes treatment: A breakthrough in stem cell therapy
- Zainab Anfaal, Zmarak Ahmed Khan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?